Close
Achema middle east
swop processing & packaging

Dainippon wins manufacturing approval for sleep inducing therapy in Japan

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

LTS Grows U.S. Footprint by Buying CDMO Renaissance Lakewood

As the U.S. production investments continue to roll in...

AstraZeneca Plant Expansion to Double Production of Lokelma

AstraZeneca has gone on to announce a newly expanded manufacturing...

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Precision Formulation in Personalized Medicine

Personalized Medicine and the Future of Precision Formulation The medical...

Dainippon Sumitomo Pharma has obtained manufacturing and marketing approval for Zolpidem tartrate tablets 5mg/10mg [DSP] from the Ministry of Health, Labour and Welfare in Japan. Zolpidem tartrate tablets 5mg/10mg [DSP] are film-coated tablets containing 5mg or 10mg of zolpidem tartrate, with a score line on one side, which are indicated for the treatment of Insomnia. The usual adult dose is once daily 5 to 10mg of zolpidem tartrate administered orally immediately before bedtime, the company said. The initial dose for elderly patients is from 5mg once daily and may be adjusted depending on age, symptoms, disease, and should not exceed 10mg once daily.

Latest stories

Related stories

LTS Grows U.S. Footprint by Buying CDMO Renaissance Lakewood

As the U.S. production investments continue to roll in...

AstraZeneca Plant Expansion to Double Production of Lokelma

AstraZeneca has gone on to announce a newly expanded manufacturing...

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression...

Precision Formulation in Personalized Medicine

Personalized Medicine and the Future of Precision Formulation The medical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »